Skip to main content
COGT $26.72 -3.70%
COGT logo
COGT · Cogent Biosciences, Inc.
Track COGT — free
$26.72 -1.03 (-3.70%) At close · Nov 20
Market Cap
$4.65B
Shares
173.99M
Volume · Nov 20 2.13M Avg daily vol (3M) 2.08M
All webcasts

Earnings call · FY2026 Q3

Cogent Biosciences, Inc. (COGT) Q3 2026 Earnings Call

Concluded Nov 5, 2026
Nov 5, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Diluted EPS -$0.59
Net income -$111.43M
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 5, 2026
Cogent Biosciences reported a $111.4 million 2026 third-quarter net loss and $791.1 million cash. Bezuclastinib FDA decision dates are November 30, 2026 for GIST, December 30, 2026 for NonAdvSM and June 29, 2027 for AdvSM.
10-Q report · filed Nov 5, 2026
Cogent has three bezuclastinib NDAs pending FDA review, with PDUFA target dates November 30, 2026, December 30, 2026 and June 29, 2027. Cash, cash equivalents and marketable securities of $791.1 million were expected to fund operations into late 2028.

The audio replay and transcript follow the call.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Full-screen source Call document